Can LDL cholesterol be too low? Possible risks of extremely low levels

被引:78
作者
Olsson, A. G. [1 ]
Angelin, B. [2 ,3 ,4 ]
Assmann, G. [5 ]
Binder, C. J. [6 ,7 ]
Bjoerkhem, I. [4 ,8 ]
Cedazo-Minguez, A. [9 ]
Cohen, J. [10 ]
von Eckardstein, A. [11 ]
Farinaro, E. [12 ]
Mueller-Wieland, D. [13 ]
Parhofer, K. G. [14 ]
Parini, P. [4 ,8 ]
Rosenson, R. S. [15 ]
Starup-Linde, J. [16 ]
Tikkanen, M. J. [17 ]
Yvan-Charvet, L. [18 ]
机构
[1] Linkoping Univ, Dept Med & Hlth, Linkoping, Sweden
[2] Karolinska Inst, Metab Unit, Dept Endocrinol Metab & Diabet, Stockholm, Sweden
[3] Karolinska Inst, KI AZ Integrated CardioMetabol Ctr, Dept Med, Stockholm, Sweden
[4] Karolinska Univ Hosp Huddinge, Stockholm, Sweden
[5] Univ Munster, Munster, Germany
[6] Med Univ Vienna, Vienna, Austria
[7] Austrian Acad Sci, Ctr Mol Med, Vienna, Austria
[8] Karolinska Inst, Div Clin Chem, Dept Lab Med, Stockholm, Sweden
[9] Karolinska Inst Huddinge, Div Neurogeriatr, Ctr Alzheimer Res, Dept Care Sci & Soc, Stockholm, Sweden
[10] UTSouthwesternMed Ctr, Dallas, TX USA
[11] Univ Zurich, Zurich, Switzerland
[12] Univ Naples Federico II, Naples, Italy
[13] Univ Cologne, Klin & Poliklin Innere Med 2, Cologne, Germany
[14] Ludwig Maximilians Univ Munchen, Munich, Germany
[15] Mt Sinai Hosp, New York, NY 10029 USA
[16] Univ Aarhus, Aarhus, Denmark
[17] Univ Helsinki, Helsinki, Finland
[18] Univ Nice Sophia Antipolis, Nice, France
关键词
abetalipoproteinaemia; adverse effects; hypocholesterolaemia; low-density lipoprotein; safety; LOW-DENSITY-LIPOPROTEIN; CORONARY-ARTERY-DISEASE; SUBTILISIN/KEXIN TYPE 9; HMG-COA REDUCTASE; MONOCLONAL-ANTIBODY; BRAIN CHOLESTEROL; FAMILIAL HYPERCHOLESTEROLEMIA; CARDIOVASCULAR-DISEASE; INTERSTITIAL FLUID; REDUCING LIPIDS;
D O I
10.1111/joim.12614
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Following the continuous accumulation of evidence supporting the beneficial role of reducing low-density lipoprotein cholesterol (LDL-C) levels in the treatment and prevention of atherosclerotic cardiovascular disease and its complications, therapeutic possibilities now exist to lower LDL-C to very low levels, similar to or even lower than those seen in newborns and nonhuman species. In addition to the important task of evaluating potential side effects of such treatments, the question arises whether extremely low LDL-C levels per se may provoke adverse effects in humans. In this review, we summarize information from studies of human cellular and organ physiology, phenotypic characterization of rare genetic diseases of lipid metabolism, and experience from clinical trials. Specifically, we emphasize the importance of the robustness of the regulatory systems that maintain balanced fluxes and levels of cholesterol at both cellular and organismal levels. Even at extremely low LDL-C levels, critical capacities of steroid hormone and bile acid production are preserved, and the presence of a cholesterol blood-brain barrier protects cells in the central nervous system. Apparent relationships sometimes reported between less pronounced low LDL-C levels and disease states such as cancer, depression, infectious disease and others can generally be explained as secondary phenomena. Drug-related side effects including an increased propensity for development of type 2 diabetes occur during statin treatment, whilst further evaluation of more potent LDL-lowering treatments such as PCSK9 inhibitors is needed. Experience from the recently reported and ongoing large event-driven trials are of great interest, and further evaluation including careful analysis of cognitive functions will be important. This is an article from the symposium: Risks and benefits of Extremely Low LDL Cholesterol.
引用
收藏
页码:534 / 553
页数:20
相关论文
共 104 条
  • [1] Mutations in PCSK9 cause autosomal dominant hypercholesterolemia
    Abifadel, M
    Varret, M
    Rabès, JP
    Allard, D
    Ouguerram, K
    Devillers, M
    Cruaud, C
    Benjannet, S
    Wickham, L
    Erlich, D
    Derré, A
    Villéger, L
    Farnier, M
    Beucler, I
    Bruckert, E
    Chambaz, J
    Chanu, B
    Lecerf, JM
    Luc, G
    Moulin, P
    Weissenbach, J
    Prat, A
    Krempf, M
    Junien, C
    Seidah, NG
    Boileau, C
    [J]. NATURE GENETICS, 2003, 34 (02) : 154 - 156
  • [2] Almeida-Montes LG, 2000, J PSYCHIATR NEUROSCI, V25, P371
  • [3] Angelin B., 2011, Oxford Textbook of Endocrinology and Diabetes, P1659
  • [4] [Anonymous], N ENGL J MED
  • [5] Levels of atherogenic lipoproteins are unexpectedly reduced in interstitial fluid from type 2 diabetes patients
    Apro, Johanna
    Parini, Paolo
    Broijersen, Anders
    Angelin, Bo
    Rudling, Mats
    [J]. JOURNAL OF LIPID RESEARCH, 2015, 56 (08) : 1633 - 1639
  • [6] Cholesterol and CSF 5-HIAA in attempted suicide
    Asellus, P.
    Nordstrom, P.
    Jokinen, J.
    [J]. JOURNAL OF AFFECTIVE DISORDERS, 2010, 125 (1-3) : 388 - 392
  • [7] Lack of Association Between the Trp719Arg Polymorphism in Kinesin-Like Protein-6 and Coronary Artery Disease in 19 Case-Control Studies
    Assimes, Themistocles L.
    Holm, Hilma
    Kathiresan, Sekar
    Reilly, Muredach P.
    Thorleifsson, Gudmar
    Voight, Benjamin F.
    Erdmann, Jeanette
    Willenborg, Christina
    Vaidya, Dhananjay
    Xie, Changchun
    Patterson, Chris C.
    Morgan, Thomas M.
    Burnett, Mary Susan
    Li, Mingyao
    Hlatky, Mark A.
    Knowles, Joshua W.
    Thompson, John R.
    Absher, Devin
    Iribarren, Carlos
    Go, Alan
    Fortmann, Stephen P.
    Sidney, Stephen
    Risch, Neil
    Tang, Hua
    Myers, Richard M.
    Berger, Klaus
    Stoll, Monika
    Shah, Svati H.
    Thorgeirsson, Gudmundur
    Andersen, Karl
    Havulinna, Aki S.
    Herrera, J. Enrique
    Faraday, Nauder
    Kim, Yoonhee
    Kral, Brian G.
    Mathias, Rasika A.
    Ruczinski, Ingo
    Suktitipat, Bhoom
    Wilson, Alexander F.
    Yanek, Lisa R.
    Becker, Lewis C.
    Linsel-Nitschke, Patrick
    Lieb, Wolfgang
    Koenig, Inke R.
    Hengstenberg, Christian
    Fischer, Marcus
    Stark, Klaus
    Reinhard, Wibke
    Winogradow, Janina
    Grassl, Martina
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2010, 56 (19) : 1552 - 1563
  • [8] Babiker A, 2005, SCAND J CLIN LAB INV, V65, P365, DOI 10.1080/00365510510025746
  • [9] Results of Bococizumab, A Monoclonal Antibody Against Proprotein Convertase Subtilisin/Kexin Type 9, from a Randomized, Placebo-Controlled, Dose-Ranging Study in Statin-Treated Subjects With Hypercholesterolemia
    Ballantyne, Christie M.
    Neutel, Joel
    Cropp, Anne
    Duggan, William
    Wang, Ellen Q.
    Plowchalk, David
    Sweeney, Kevin
    Kaila, Nitin
    Vincent, John
    Bays, Harold
    [J]. AMERICAN JOURNAL OF CARDIOLOGY, 2015, 115 (09) : 1212 - 1221
  • [10] Risk of new-onset diabetes associated with statin use
    Beckett, Robert D.
    Schepers, Sarah M.
    Gordon, Sarah K.
    [J]. SAGE OPEN MEDICINE, 2015, 3